Xenon Pharmaceuticals Target of Unusually High Options Trading (NASDAQ:XENE)

Xenon Pharmaceuticals Inc. (NASDAQ:XENE) saw unusually large options trading activity on Wednesday. Stock traders acquired 4,063 put options on the stock. This is an increase of approximately 2,362% compared to the average volume of 165 put options.

Xenon Pharmaceuticals Trading Up 2.0%

Shares of XENE stock opened at $42.51 on Thursday. The stock has a market cap of $3.29 billion, a P/E ratio of -10.93 and a beta of 0.96. Xenon Pharmaceuticals has a twelve month low of $26.74 and a twelve month high of $46.60. The stock has a 50 day moving average of $42.48 and a 200 day moving average of $40.58.

Insider Transactions at Xenon Pharmaceuticals

In other Xenon Pharmaceuticals news, CEO Ian Mortimer sold 40,000 shares of the firm’s stock in a transaction on Friday, January 2nd. The shares were sold at an average price of $44.43, for a total value of $1,777,200.00. Following the completion of the transaction, the chief executive officer owned 6,000 shares of the company’s stock, valued at approximately $266,580. This trade represents a 86.96% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. In the last quarter, insiders have sold 65,302 shares of company stock worth $2,924,128. Corporate insiders own 4.07% of the company’s stock.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the company. Elevation Point Wealth Partners LLC purchased a new stake in shares of Xenon Pharmaceuticals during the 2nd quarter worth about $32,000. Danske Bank A S purchased a new position in Xenon Pharmaceuticals during the third quarter worth approximately $32,000. Blue Trust Inc. grew its holdings in Xenon Pharmaceuticals by 2,560.7% in the fourth quarter. Blue Trust Inc. now owns 745 shares of the biopharmaceutical company’s stock valued at $33,000 after purchasing an additional 717 shares during the period. Kestra Advisory Services LLC acquired a new stake in Xenon Pharmaceuticals in the fourth quarter valued at approximately $33,000. Finally, Aster Capital Management DIFC Ltd purchased a new stake in shares of Xenon Pharmaceuticals in the third quarter valued at approximately $39,000. Hedge funds and other institutional investors own 95.45% of the company’s stock.

Analyst Upgrades and Downgrades

Several research firms recently issued reports on XENE. Cantor Fitzgerald reissued an “overweight” rating and issued a $55.00 target price on shares of Xenon Pharmaceuticals in a research report on Tuesday, November 4th. Weiss Ratings reissued a “sell (d-)” rating on shares of Xenon Pharmaceuticals in a report on Friday, January 9th. Stifel Nicolaus set a $66.00 price objective on Xenon Pharmaceuticals in a research note on Tuesday, February 10th. Needham & Company LLC reiterated a “buy” rating and issued a $55.00 target price on shares of Xenon Pharmaceuticals in a research report on Tuesday, November 4th. Finally, Royal Bank Of Canada increased their price target on shares of Xenon Pharmaceuticals from $55.00 to $58.00 and gave the stock an “outperform” rating in a report on Tuesday, November 4th. Two equities research analysts have rated the stock with a Strong Buy rating, ten have given a Buy rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, the stock currently has a consensus rating of “Buy” and a consensus price target of $54.73.

About Xenon Pharmaceuticals

Xenon Pharmaceuticals Inc is a clinical‐stage biopharmaceutical company dedicated to discovering and developing novel, small‐molecule drugs targeting ion channels in the central and peripheral nervous system. The company’s research focus centers on neurological and pain disorders—including epilepsy, migraine, and neuropathic pain—by modulating key ion‐channel proteins to restore normal neuronal function. Xenon’s scientific platform draws upon advances in ion‐channel biology and structure‐based drug design to identify and optimize therapeutic candidates with the potential for improved safety and efficacy profiles compared with existing treatments.

The company’s pipeline comprises multiple preclinical and clinical programs.